<DOC>
	<DOC>NCT01874340</DOC>
	<brief_summary>To evaluate the efficacy and safety of AIN457 versus placebo in patients with relapsing multiple sclerosis.</brief_summary>
	<brief_title>Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis of Multiple Sclerosis according to 2010 revised McDonald criteria Disease duration of 10 years or less At least one relapse in the last year EDSS score 0 to 5.0 at entry Active chronic disease of the immune system other than multiple sclerosis History of malignancy within the past 5 years Active systemic bacterial, viral or fungal infections Previous treatment with more than one class of multiple sclerosis therapies except for previous treatment with glatiramer acetate and interferonbeta(s) Any medically unstable condition Unable to undergo MRI scans or repeated blood tests Pregnant or nursing females Women of childbearing potential must use reliable forms of contraception Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>AIN457</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
</DOC>